DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9lqbqq/rheumatoid) has announced the addition of the "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs" report to their offering.
The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021
The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron's sarilumab, Johnson & Johnson/GlaxoSmithKline's [J&J/GSK's] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte's baricitinib, Loss of patent exclusivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.
Reasons to Purchase:
- Understand the RA pipeline and the key trends in the current product development landscape
- Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be
- Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Marketed Products
4 Product Pipeline
5 Market Forecasts
6 Deals
7 Appendix
Companies Mentioned
- AbbVie
- Abbott Laboratories
- Ablynx
- Alder Biopharmaceuticals
- Amgen
- Archemix
- Astellas Pharma
- AstraZeneca
- Biogen IDEC
- Bristol-Myers Squibb
- Chroma Therapeutics
- Eli Lilly
- Galapagos
- Genentech
- GlaxoSmithKline
- Janssen Biotech
- Johnson & Johnson
- Merck
- Pfizer
- Regeneron Pharmaceuticals/Sanofi
- Rigel Pharma
- Roche
- Takeda Pharmaceutical
- UCB
- Vertex Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/9lqbqq/rheumatoid
